Trasis and KU Leuven agreement

TRASIS is reinforcing its long-standing collaboration with KU Leuven (KUL), a recognized leader in radiopharmaceutical sciences and nuclear medicine. This new step reflects a shared ambition: developing next-generation technologies that support the evolution of targeted therapies.

A complementary approach from research to industrialization

Built on more than 10 years of close interaction, this collaboration reflects a strong alignment in expertise and working dynamics, resulting in a natural complementarity between both partners. KU Leuven brings expertise in the development of novel radiopharmaceutical molecules, while Trasis ensures their translation into robust, scalable industrial solutions.

Together, they create a continuum from molecule design to industrial application, accelerating the transition from innovation to clinical reality, an approach that reflects the type of partnerships Trasis is committed to fostering to drive next-generation developments.

Enabling innovation through strategic access

A key dimension of this strengthened collaboration lies in the strategic access to critical radioisotopes, including alpha emitters, beta-minus emitters and positron-emitting (beta-plus) isotopes, essential for nuclear medicine and theranostic applications.

Far from being a purely technical aspect, this access is a true enabler, allowing Trasis to:

Develop its own solutions with greater autonomy
Increase flexibility in project design and execution
Expand development capabilities across a broader range of applications

At the same time, this framework creates new opportunities to initiate joint projects, where each partner can fully leverage its specific expertise.

A partnership built on excellence and continuity

Choosing KU Leuven as a partner is no coincidence. The institution is widely recognized for its excellence in radiopharmacy and nuclear medicine, supported by leading experts such as Prof. Guy Bormans, known for his work on neurotracers, and Prof. Frederik Cleeren, whose research focuses on radiometals and theranostics.

Prof. Frederik Cleeren, KU Leuven: “Collaborating with Trasis allows us to extend the impact of our research beyond the laboratory, ensuring that innovative tracers can be translated into robust solutions for clinical use.”

Corentin Warnier, Head of Chemistry, Trasis: “By bringing together KU Leuven’s research strengths and Trasis’ industrial expertise, we aim to turn innovation into real patient access more quickly. This collaboration builds on a trusted, long-standing relationship and strengthens a partnership that has already delivered strong results.”

This strengthened collaboration marks an important step forward. It reflects not only the continuation of a successful partnership, but also Trasis’ ambition to play a central role in the development and industrialization of next-generation theranostic solutions.

TRASIS and KU Leuven: advancing next-generation targeted therapies through a strengthened collaboration